nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.03.2014 | Original Paper

High expression of metabotropic glutamate receptor 4: correlation with clinicopathologic characteristics and prognosis of osteosarcoma

verfasst von: Wu Yang, He Maolin, Zhao Jinmin, Wang Zhe

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Analyze protein and gene expression of mGluRs (mGluR1, mGluR5, mGluR4) in osteosarcoma tissues and discuss the relation between expression level and clinical characteristics of osteosarcoma, and study the clinical significance.

Methods

Detect protein and mRNA expression level of mGluRs (mGluR1, mGluR5, mGluR4) in 40 osteosarcoma tissues and the corresponding adjacent normal tissues by Western blot and RT-PCR accordingly. Immunohistochemistry was adopted to detect the expression of mGluRs (mGluR1, mGluR5, mGluR4) in 118 paraffin embedded osteosarcoma tissues and eight normal bone tissues. Then, the correlation between the expression and clinical characteristics of patients was analyzed. Furthermore, survival analysis of osteosarcoma was performed to study the relation between expression level of mGluRs and patient prognosis.

Results

No correlation of mGluR1 and mGluR5 with clinicopathologic characteristics of osteosarcoma was found. Statistical analysis demonstrated that the expression level of mGluR4 shared no significant correlation with gender, age, histologic type and tumor location of patient, but was related to Enneking stage and tumor metastasis (P < 0.05). High mGluR4 expression is more frequently noted in the osteosarcoma tissues with higher Enneking stage and metastasis. The results of Western blot and RT-PCR indicated a significantly increased expression level of mGluR4 gene and protein in osteosarcoma tissues compared with normal tissues. Though higher gene and protein expression of mGluR5 and mGluR1 were also indicated in osteosarcoma tissues compared with normal tissues, no statistical significance was noted for the difference (P > 0.05). According to the survival analysis of 118 osteosarcoma patients, cases in the mGluR4 high-expression group showed inferior disease-free survival rate and poorer overall survival rate.

Conclusion

High expression of mGluR4 in osteosarcoma tissues is related to poor prognosis, thus holding certain reference value for estimating prognosis of osteosarcoma patients.

Aramori I, Nakanishi S (1992) Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells. Neuron 8:757–765PubMedCrossRef

Brice NL, Varadi A, Ashcroft SJ et al (2002) Metabotropic glutamate and GABA (B) receptors contribute to the modulation of glucose-stimulated insulin secretion in pancreatic beta cells. Diabetologia 45:242–252PubMedCrossRef

Brocke KS, Staufner C, Luksch H et al (2010) Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther 9:455–468PubMedCrossRef

Carrle D, Bielack S (2009) Osteosarcoma lung metastases detection and principles of multimodal therapy. Cancer Treat Res 152:165–184PubMedCrossRef

Chang HJ, Yoo BC, Lim SB et al (2005) Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res 11:3288–3295PubMedCrossRef

Errani C, Longhi A, Rossi G et al (2011) Palliative therapy for osteosarcoma. Expert Rev Anticancer Ther 11:217–227PubMedCrossRef

Genever PG, Maxfield SJ, Kennovin GD et al (1999) Evidence for a novel glutamate-mediated signaling pathway in keratinocytes. J Invest Dermatol 112:337–342PubMedCrossRef

Gill J, Ahluwalia MK, Geller D et al (2013) New targets and approaches in osteosarcoma. Pharmacol Ther 137:89–99PubMedCrossRef

Griffin KJ, Kirschner LS, Matyakhina L et al (2004) A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase a develops endocrine and other tumours: comparison with Carney Complex and other PRKAR1A induced lesions. J Med Genet 41:923–931PubMedCrossRef

Harting MT, Blakely ML (2006) Management of osteosarcoma pulmonary metastases. Semin Pediatr Surg 15:25–29PubMedCrossRef

Iacovelli L, Bruno V, Salvatore L et al (2002) Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways. J Neurochem 82:216–223PubMedCrossRef

Kalariti N, Lembessis P, Koutsilieris M (2004) Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. Anticancer Res 24:3923–3929PubMed

Marinissen MJ, Gutkind JS (2001) G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 22:368–376PubMedCrossRef

Molyneux SD, Di Grappa MA, Beristain AG et al (2010) Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest 120:3310–3325PubMedCentralPubMedCrossRef

Park SY, Lee SA, Han IH et al (2007) Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncol Rep 17:81–87PubMed

Patton AJ, Genever PG, Birch MA et al (1998) Expression of an N-methyl-D-aspartate-type receptor by human and rat osteoblasts and osteoclasts suggests a novel glutamate signaling pathway in bone. Bone 22:645–649PubMedCrossRef

Peavy RD, Chang MS, Sanders-Bush E et al (2001) Metabotropic glutamate receptor 5-induced phosphorylation of extracellular signal-regulated kinase in astrocytes depends on transactivation of the epidermal growth factor receptor. J Neurosci 21:9619–9628PubMed

Pollock PM, Cohen-Solal K, Sood R et al (2003) Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 34:108–112PubMedCrossRef

Savage SA, Mirabello L, Wang Z et al (2013) Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet 45:799–803PubMedCentralPubMedCrossRef

Seidlitz EP, Sharma MK, Saikali Z et al (2009) Cancer cell lines release glutamate into the extracellular environment. Clin Exp Metastasis 26:781–787PubMedCrossRef

Seidlitz EP, Sharma MK, Singh G (2010) Extracellular glutamate alters mature osteoclast and osteoblast functions. Can J Physiol Pharmacol 88:929–936PubMedCrossRef

Sharma MK, Seidlitz EP, Singh G (2010) Cancer cells release glutamate via the cystine/glutamate antiporter. Biochem Biophys Res Commun 391:91–95PubMedCrossRef

Skerry TM (2008) The role of glutamate in the regulation of bone mass and architecture. J Musculoskelet Neuronal Interact 8:166–173PubMed

Skerry TM, Genever PG (2001) Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci 22:174–181PubMed

Stepulak A, Luksch H, Gebhardt C et al (2009) Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol 132:435–445PubMed

Takano T, Lin JH, Arcuino G et al (2001) Glutamate release promotes growth of malignant gliomas. Nat Med 7:1010–1015PubMed

Tanabe Y, Masu M, Ishii T et al (1992) A family of metabotropic glutamate receptors. Neuron 8:169–179PubMed

Teh J, Chen S (2012) mGlu Receptors and cancerous growth. Wiley Interdiscip Rev Membr Transp Signal 1:211–220PubMedCentralPubMed

Thandi S, Blank JL, Challiss RA (2002) Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways. J Neurochem 83:1139–1153PubMed

Traynelis SF, Wollmuth LP, McBain CJ et al (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62:405–496PubMed

Titel: High expression of metabotropic glutamate receptor 4: correlation with clinicopathologic characteristics and prognosis of osteosarcoma
verfasst von: Wu Yang
He Maolin
Zhao Jinmin
Wang Zhe
Publikationsdatum: 01.03.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2014
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-013-1581-3

Springer Medizin

High expression of metabotropic glutamate receptor 4: correlation with clinicopathologic characteristics and prognosis of osteosarcoma

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers

Imbalance in redox status is associated with tumor aggressiveness and poor outcome in lung adenocarcinoma patients

Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer

Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML)

High FDG uptake predicts poorer survival in locally advanced nonsmall cell lung cancer patients undergoing curative radiotherapy, independently of tumor size

Plasma tumor necrosis factor-α and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie